Annexon Inc (NASDAQ: ANNX) — Perfil da empresa, notícias e dados financeiros
Annexon is a biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative disorders targeting key immune pathways.
Annexon Inc
Annexon (NASDAQ:ANNX) is a biopharmaceutical company focused on developing novel therapies for patients with autoimmune and neurodegenerative disorders. Their innovative approach targets the classical complement cascade, a crucial part of the immune system, aiming to halt or prevent the progression of these conditions. The company's portfolio includes several candidates in clinical trials, targeting diseases like Guillain-Barre Syndrome, amyotrophic lateral sclerosis (ALS), and Huntington's disease, among others. With a commitment to transforming the lives of patients through groundbreaking research, Annexon's objective is to pioneer treatments that can significantly improve outcomes for individuals facing these challenging diseases.
Resumo
Operações
Produtos e/ou serviços de Annexon Inc
- ANX005: This drug candidate is likely in development for treating a specific classical complement-mediated disorder.
- ANX007: Similar to ANX005, this is an investigational drug candidate targeting another classical complement-mediated disorder.
- ANX1502: This candidate focuses on a different approach. It might be an oral small molecule inhibitor of the classical complement pathway, potentially for a broader range of classical complement-mediated disorders compared to ANX005 or ANX007.
- ANX009: This investigational drug candidate is likely targeted towards a specific classical complement-mediated disease affecting the eye or surrounding tissues (ophthalmic disease).
equipe executiva do Annexon Inc
- Douglas E. LoveCEO, President & Director
- Jennifer LewExecutive VP, CFO & Corporate Secretary
- Ted YednockExecutive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
- Dean R. ArtisChief Scientific Officer & Executive VP
- Linda A. FitzpatrickChief Human Resources Officer
- Michael OverdorfExecutive VP & Chief Business Officer
- Henk-Andre KroonSenior Vice President of Translational Medicine
- Jamie DananbergExecutive VP & Chief Medical Officer
- Shikhar AgarwalSenior VP & Head of Commercial
- Sunil MehtaSenior VP of Medical Affairs
Últimas notícias sobre a Annexon Inc
Principais indicadores financeiros
Resultados divulgados pela Annexon Inc, em USD.
- Cap. de mercado
- 765,9 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -216,4 mi | -206,7 mi | |
| 0 | -154,1 mi | -138,2 mi | |
| 0 | -143,7 mi | -134,2 mi | |
| 0 | -145,6 mi | -138,3 mi |